Advertisement

2012 Genitourinary Cancers Symposium

Prostate Cancer

Two Novel Agents Prolong Survival in Advanced Prostate Cancer

Two novel agents with distinct mechanisms of action join ranks of treatments that extend survival for patients with castration-resistant prostate cancer: MDV3100 and radium-223. Both drugs achieved a ...

Prostate Cancer

Immune Changes Reported with Early Use of Sipuleucel-T in Neoadjuvant Setting for Prostate Cancer

Sipuleucel-T (Provenge) can generate a circulating immune response to treat men with metastatic castrate-resistant prostate cancer, as per its FDA-approved indication.1 A neoadjuvant trial was perform...

Prostate Cancer
Bladder Cancer
Kidney Cancer

Important News Briefs: New Data Reported in Prostate, Bladder, and Kidney Cancers

The recent 2012 Genitourinary Cancers Symposium featured a wealth of presentations on prostate, bladder, kidney, and other genitourinary cancers. Brief summaries of some of the oral and poster session...

Prostate Cancer

Expert Point of View: Prostate Cancer Studies Compare Outcomes, Toxicities, and Costs

Nicholas B. Vogelzang, MD, moderator of the press briefing where these findings were presented, agreed that the first study supports intensity-modulated radiotherapy (IMRT) as the current standard of ...

Prostate Cancer

Prostate Cancer Studies Compare Outcomes, Toxicities, and Costs

Patients with prostate cancer are treated with various forms of radiotherapy and/or radical prostatectomy with little comparative data to inform treatment selection. Two studies presented at the 2012 ...

Research of Two 2012 Foundation Merit Award Recipients Highlighted

Studies led by Nathan Sheets, MD, and Mark Jesus Magbanua, PhD, were recently featured in the Genitourinary Cancers Symposium press program. Both researchers are 2012 Conquer Cancer Foundation of ASCO...

Prostate Cancer

SELECT Trial Update: Vitamin E Fails to Prevent Prostate Cancer in Healthy Men, Appears to Increase Risk

Supplements touted as preventing prostate cancer may turn out to be dangerous, as is evident from updated results of the largest long-term prevention trial, called the Selenium and Vitamin E Cancer Pr...

Prostate Cancer

Short-term Hormone Therapy Did Not Increase Risk of Cardiovascular Death in Men with Localized Prostate Cancer, RTOG 94-08 Trial Finds

Short-term androgen deprivation therapy does not appear to increase cardiovascular mortality in men with clinically localized prostate cancer, according to a post hoc analysis of a large Radiation The...

Bladder Cancer

Study Shows Concurrent Chemoradiation Therapy to be a Viable Strategy for Muscle-invasive Bladder Cancer

Combined-modality therapy provides a bladder-sparing alternative to radical cystectomy with comparable outcomes in patients with muscle-invasive bladder cancer, according to a pooled analysis of six R...

Prostate Cancer

Advances in Prostate Cancer Accompanied by Ongoing Debates

Scientific advances have markedly improved prostate cancer survival, but this clinical success story is not without its share of controversy. From screening through treatment, a growing array of optio...

Advertisement

Advertisement



Advertisement

click me